Is Rocket Pharmaceuticals Stock a Good Investment?
Rocket Pharmaceuticals Investment Advice | RCKT |
- Examine Rocket Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Rocket Pharmaceuticals' leadership team and their track record. Good management can help Rocket Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Rocket Pharmaceuticals' business and its evolving consumer preferences.
- Compare Rocket Pharmaceuticals' performance and market position to its competitors. Analyze how Rocket Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Rocket Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Rocket Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Rocket Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Rocket Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Rocket Pharmaceuticals Stock
Researching Rocket Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 97.0% of the company shares are owned by institutional investors. The book value of Rocket Pharmaceuticals was at this time reported as 3.62. The company has Price/Earnings To Growth (PEG) ratio of 0.03. Rocket Pharmaceuticals recorded a loss per share of 2.73. The entity last dividend was issued on the 5th of January 2018. The firm had 1:4 split on the 5th of January 2018.
To determine if Rocket Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Rocket Pharmaceuticals' research are outlined below:
| Rocket Pharmaceuticals generated a negative expected return over the last 90 days | |
| Rocket Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (245.59 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Rocket Pharmaceuticals currently holds about 321.37 M in cash with (194.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.87. | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference |
Rocket Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Rocket Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Rocket Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Rocket Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Rocket Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2018-08-08 | 2018-06-30 | -0.36 | -0.4 | -0.04 | 11 | ||
2020-08-05 | 2020-06-30 | -0.51 | -0.45 | 0.06 | 11 | ||
2020-11-04 | 2020-09-30 | -0.46 | -0.53 | -0.07 | 15 | ||
2022-11-03 | 2022-09-30 | -0.79 | -0.87 | -0.08 | 10 | ||
2018-05-11 | 2018-03-31 | -0.33 | -0.42 | -0.09 | 27 | ||
2021-08-09 | 2021-06-30 | -0.65 | -0.55 | 0.1 | 15 | ||
2020-03-05 | 2019-12-31 | -0.49 | -0.39 | 0.1 | 20 | ||
2019-11-07 | 2019-09-30 | -0.49 | -0.38 | 0.11 | 22 |
Know Rocket Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Rocket Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Rocket Pharmaceuticals backward and forwards among themselves. Rocket Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Rocket Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 1.6 M | Boxer Capital Llc | 2024-09-30 | 1.5 M | Bank Of America Corp | 2024-06-30 | 1.2 M | Pictet Asset Manangement Sa | 2024-06-30 | 1.2 M | Cowen And Company, Llc | 2024-06-30 | 1.1 M | Novo A/s | 2024-09-30 | 1.1 M | Mpm Oncology Impact Management Lp | 2024-09-30 | 1.1 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 952 K | Perceptive Advisors Llc | 2024-09-30 | 931.9 K | Rtw Investments, Llc | 2024-06-30 | 17.7 M | Wellington Management Company Llp | 2024-06-30 | 9.2 M |
Rocket Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.29 B.Market Cap |
|
Rocket Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.49) | (0.51) | |
| Return On Capital Employed | (0.50) | (0.53) | |
| Return On Assets | (0.43) | (0.46) | |
| Return On Equity | (0.50) | (0.52) |
Determining Rocket Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Rocket Pharmaceuticals is a good buy. For example, gross profit margin measures Rocket Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Rocket Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Rocket Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Rocket Pharmaceuticals. Check Rocket Pharmaceuticals' Beneish M Score to see the likelihood of Rocket Pharmaceuticals' management manipulating its earnings.
Evaluate Rocket Pharmaceuticals' management efficiency
Rocket Pharmaceuticals has return on total asset (ROA) of (0.3448) % which means that it has lost $0.3448 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5927) %, meaning that it created substantial loss on money invested by shareholders. Rocket Pharmaceuticals' management efficiency ratios could be used to measure how well Rocket Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.51 in 2024. Return On Capital Employed is likely to drop to -0.53 in 2024. At this time, Rocket Pharmaceuticals' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 29.4 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 292.8 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.86 | 6.16 | |
| Tangible Book Value Per Share | 5.10 | 5.35 | |
| Enterprise Value Over EBITDA | (10.51) | (11.04) | |
| Price Book Value Ratio | 5.11 | 5.37 | |
| Enterprise Value Multiple | (10.51) | (11.04) | |
| Price Fair Value | 5.11 | 5.37 | |
| Enterprise Value | 2.5 B | 2.6 B |
Understanding the management dynamics of Rocket Pharmaceuticals allows us to gauge its ability to sustain growth and profitability. This comprehensive analysis aids in determining the stock's value.
Beta 1.089 |
Basic technical analysis of Rocket Stock
As of the 29th of November, Rocket Pharmaceuticals holds the Coefficient Of Variation of (1,032), variance of 15.01, and Risk Adjusted Performance of (0.07). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Rocket Pharmaceuticals, as well as the relationship between them.Rocket Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Rocket Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Rocket Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Rocket Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Rocket Pharmaceuticals' Outstanding Corporate Bonds
Rocket Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Rocket Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Rocket bonds can be classified according to their maturity, which is the date when Rocket Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| US77314EAA64 Corp BondUS77314EAA64 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| US77310VAA26 Corp BondUS77310VAA26 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| US77313LAA17 Corp BondUS77313LAA17 | View |
Understand Rocket Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Rocket Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.19) | |||
| Mean Deviation | 2.83 | |||
| Coefficient Of Variation | (1,032) | |||
| Standard Deviation | 3.87 | |||
| Variance | 15.01 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.60) | |||
| Total Risk Alpha | (0.97) | |||
| Treynor Ratio | (0.20) | |||
| Maximum Drawdown | 21.07 | |||
| Value At Risk | (5.67) | |||
| Potential Upside | 6.59 | |||
| Skewness | 0.9598 | |||
| Kurtosis | 2.21 |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.19) | |||
| Mean Deviation | 2.83 | |||
| Coefficient Of Variation | (1,032) | |||
| Standard Deviation | 3.87 | |||
| Variance | 15.01 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.60) | |||
| Total Risk Alpha | (0.97) | |||
| Treynor Ratio | (0.20) | |||
| Maximum Drawdown | 21.07 | |||
| Value At Risk | (5.67) | |||
| Potential Upside | 6.59 | |||
| Skewness | 0.9598 | |||
| Kurtosis | 2.21 |
Consider Rocket Pharmaceuticals' intraday indicators
Rocket Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Rocket Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Rocket Pharmaceuticals Corporate Filings
F4 | 25th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 18th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F3 | 11th of September 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Rocket Stock media impact
Far too much social signal, news, headlines, and media speculation about Rocket Pharmaceuticals that are available to investors today. That information is available publicly through Rocket media outlets and privately through word of mouth or via Rocket internal channels. However, regardless of the origin, that massive amount of Rocket data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Rocket Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Rocket Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Rocket Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Rocket Pharmaceuticals alpha.
Rocket Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Rocket Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Rocket Pharmaceuticals Corporate Management
| CPA CPA | VP, Officer | Profile | |
| Mayo Pujols | Chief Officer | Profile | |
| Martin JD | Chief Counsel | Profile | |
| Carlos Martin | Chief Officer | Profile | |
| Jonathan Schwartz | Chief Medical Officer | Profile | |
| Aaron Ondrey | Chief Officer | Profile | |
| Isabel JD | Senior Officer | Profile |
Additional Tools for Rocket Stock Analysis
When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.